General Surgery Malpractice Insurance in New York: A 2026 Rate & Risk Guide

TL;DR. New York general surgery malpractice premium ranges from roughly $27K in Rochester to around $142K on Long Island at $1M/$3M claims-made limits, driven by a high-severity claim profile (bile-duct injury, retained foreign body, bowel perforation, missed appendicitis) and no state damage caps. Lavern's Law now extends the reporting window for cancer misdiagnosis claims to 7 years from the alleged negligence, which reshapes tail planning for every retiring NY general surgeon.

High-severity claims profile

General surgery sits in the top quartile of U.S. malpractice severity. PIAA data has long placed surgery-related claims among the most expensive on a paid-indemnity basis, and Harvard's CRICO Comparative Benchmarking System documents that about 23% of all surgical claims involve high-severity injury or death (CRICO Strategies, 2022). That severity level is what drives NY general surgery base rates above most other non-OB specialties.

The four high-severity claim pathways

Four claim types dominate NY general surgery severity. Retained foreign body, most often a surgical sponge or needle fragment left at the operative site, is the prototype "never event" and produces nuclear-verdict exposure even when clinical harm is modest. The American College of Surgeons reports retained surgical items occur in roughly 1 in 5,500 operations (ACS Bulletin, 2019), and NY juries treat them as per se negligence.

Bile duct injury during laparoscopic cholecystectomy is the second recurring pathway. Published rates cluster around 0.3–0.5% of cholecystectomies, with higher rates in low-volume centers. Bowel perforation recognized late, whether during laparoscopic entry, colonoscopy-adjacent operations, or adhesiolysis, is the third. The fourth, delayed or missed diagnosis of appendicitis or mesenteric ischemia, implicates both the operating surgeon and the emergency physician who made the initial call.

Each pathway produces seven-figure indemnity risk in downstate NY venues. The American College of Surgeons' NSQIP dataset documents post-operative morbidity and mortality rates that anchor the underwriting view of general surgery risk (ACS NSQIP, 2024).

Anesthesia interaction and shared liability

General surgeons in NY carry partial exposure for intra-operative anesthesia events under joint-and-several liability rules. An aspiration, a post-induction arrest, or an airway-management failure implicates both the anesthesiologist and the surgeon of record, and NY jury instructions on joint responsibility frequently produce split verdicts that a single carrier's primary limit cannot absorb. Defense strategy in these cases turns on pre-operative documentation, anesthesia consent, and the operative note's record of intra-operative awareness.

Carriers underwrite this exposure by asking about anesthesia model (hospital-employed, group-contracted, or individually credentialed), operative volume in ambulatory surgery centers, and the surgeon's documented pre-op clearance protocol. A general surgeon operating at a mix of hospital ORs and an ASC where the anesthesia group is separately credentialed often sees higher underwriting scrutiny than one who operates exclusively within a single hospital's employed-anesthesia model.

Severity distribution and reserve dynamics

The severity distribution matters as much as the raw frequency. CRICO CBS data places general surgery paid claims with a median indemnity well into six figures, with a long right tail of verdicts in the $2M–$10M range in states without caps. New York's no-cap regime, combined with the downstate verdict history, shifts that tail further right. The National Practitioner Data Bank's 2024 state summary showed NY led the nation in total medical malpractice payouts, at roughly $550M across 1,205 reports (NPDB Public Use File, 2024).

For a general surgeon, that translates to a reserve profile where a single claim can consume 10–15% of a career's accumulated tail funding. The actuarial logic behind the 150–200% tail multiplier is this reserve math: the carrier must fund defense and indemnity for a reporting window that extends well past retirement, with no future premium stream to replenish it. Our deeper breakdown of occurrence versus claims-made mechanics walks through how that reserve profile changes with policy structure.

How underwriters read a general surgeon's application

Carrier underwriters assess three things before pricing a NY general surgery risk. First, the operative mix: a surgeon doing predominantly outpatient hernia and cholecystectomy prices differently from one doing hepatobiliary and oncologic resections, even at the same zip code. Second, the prior five-year claims history: any paid claim, open reserve, or unreported incident triggers schedule-rating debits. Third, the supervisory structure: whether residents, fellows, or APPs operate under the surgeon's name on billing.

The application itself typically runs 12 to 18 pages, with an attached operative log for the prior 12 months. Underwriters pay specific attention to robotic surgery volume, bariatric case counts, and any trauma call hours at Level I or II centers. Surgeons with a mature, narrow operative profile quote faster and cleaner than those whose case log spans three or four sub-specialty areas.

NY carrier options for general surgery

Six carriers write the substantial majority of NY general surgery risk: MLMIC (the Berkshire Hathaway subsidiary insuring more than 13,000 NY physicians, per the company's own disclosure at mlmic.com), EmPRO (formerly PRI), The Doctors Company, MedPro Group, ProMutual/Coverys, and CNA. The statutory MMIP Pool absorbs surgeons declined by the voluntary market. Each carrier prices retro dates, scope endorsements, and tail multipliers on its own grid, which is why a multi-carrier quote produces a very different number than a single published rate.

MLMIC: the NY anchor carrier

MLMIC has written the largest share of NY physician risk for more than 45 years and insures over 13,000 physicians statewide. Its 2018 acquisition by Berkshire Hathaway's National Indemnity platform added capital depth and converted MLMIC from a mutual to a stock insurer. For a general surgeon, MLMIC's appeal is its NY-only book: every territory factor, every scope endorsement, and every claims-handling protocol is calibrated to NY statute and venue, rather than adapted from a national rating plan.

MLMIC's general surgery appetite covers the full scope from outpatient hernia repair to hepatobiliary and complex oncologic resections. The carrier's territory grid divides the state into six zones, with Long Island at the top end and Rochester at the bottom. Filed rate pages on the NY Department of Financial Services rate database resolve to zones but not to the full carrier-specific modifier stack, which is why two MLMIC-appointed brokers can quote the same surgeon differently based on endorsement assumptions.

EmPRO and The Doctors Company: the NY voluntary alternatives

EmPRO, formerly Physicians' Reciprocal Insurers, is NY's third-largest admitted MPL insurer. Public filings show $190.2M in gross written premium and an 87.9% combined ratio for 2024 (EmPRO via Business Wire, 2024), numbers that signal disciplined underwriting and sustainable pricing. EmPRO's territory grid is more granular than MLMIC's in Brooklyn and Queens, which can advantage Queens-based general surgeons on a same-zip-code quote.

The Doctors Company (TDC) is a physician-owned national mutual and the largest U.S. MPL writer by policyholder count. In NY, TDC's general surgery book skews toward employed physicians at hospital-affiliated groups and multi-state practices because TDC can write consistent limits across state lines where MLMIC and EmPRO are NY-only. TDC also publishes dividend history that matters to long-horizon physicians planning toward retirement.

MedPro, Coverys, CNA, and the MMIP Pool

MedPro Group, part of Berkshire Hathaway's broader health insurance platform, writes NY general surgery primarily on hospital-group and health-system placements. Coverys (formerly ProMutual) competes on multi-state programs and certain academic medical center arrangements. CNA appears on some employed-physician risk-transfer programs but does not write a dominant share of independent NY general surgery books.

The New York Medical Malpractice Insurance Plan (MMIP) is the statutory placement of last resort. General surgeons declined by all voluntary admitted carriers are assigned to MMIP, which spreads the risk across all admitted NY MPL writers by pro-rata share under NY Insurance Law. Premium runs at a surcharge to voluntary-market rates, and reported reasons for assignment, typically claim frequency, disciplinary history, or high-severity case mix, are disclosed to the assigned carrier. Most surgeons will never touch MMIP. For those who do, the plan exists so coverage is always available, not so it is priced attractively.

For a carrier-by-carrier context that sits above this specialty focus, see our NY medical malpractice pillar guide.

Retroactive date handling across carriers

Retroactive date continuity is the single most important field when a general surgeon moves between voluntary-market carriers. MLMIC, EmPRO, and TDC routinely accept continuous retro for surgeons with a clean five-year claims record, meaning the incoming carrier honors the earliest act covered under the departing policy. When retro is limited rather than continuous, every operative case before the new policy's inception becomes uninsured unless tail is purchased from the departing carrier.

Three recurring errors derail carrier switches. Binding the new policy before receiving written retro confirmation. Allowing the departing policy to lapse for a day or more between termination and the new effective date. Failing to confirm whether any open incident or reserve will follow the surgeon to the new carrier's claims-history file. Each error is preventable with a written retro-acceptance letter filed in the surgeon's personal credentialing packet.

NY general surgery cost table by zone

At $1M/$3M claims-made limits, a mid-career NY general surgeon's annual premium ranges from roughly $27K in Rochester, Buffalo, and Syracuse to around $142K on Long Island before individual claims-history credits or debits. Statewide base rates cluster between $110K–$125K in carrier filings, and downstate territory factors of 1.3–1.7 produce the top-end numbers. The broker-benchmark annual average across NY general surgery in 2026 sits near $112K, with the mean pulled upward by the downstate concentration of higher-volume surgeons.

Premium and tail ranges by zone

Why upstate and downstate diverge by 5×

Territory factors are the single largest driver of NY general surgery premium variance. MLMIC's grid sets Rochester and much of the Southern Tier at roughly 0.5, while Nassau and Suffolk counties run at 1.7 or higher. That spread, layered on a statewide base around $115K for mid-career general surgery, produces the 5× range between Rochester and Long Island shown above. Jury-verdict history is the underlying driver: Nassau County Supreme Court has concentrated nuclear verdicts over the past decade, and carriers price accordingly.

Published rate filings on the NY DFS rate database resolve to zones but not to the full modifier stack. A general surgeon benchmarking premium from published tables alone will understate the downstate variance between carriers by 10–20%. The reliable path is a multi-carrier quote comparison in the actual practice zip code.

Reading the tail column

Tail estimates in the table above assume a 200% multiplier on the upper bound of each annual range, which matches typical carrier practice for general surgery. The actual multiplier ranges from roughly 150% for specialties with shorter reporting-development curves to 200% or slightly above for general surgery, which sits near the top of the severity distribution. For context on the mechanics and timing of tail, see our detailed walkthrough of when tail coverage is required and how it is priced.

How claims history modifies the base

The table reflects mid-career general surgery at standard limits with no significant paid-claim history. Carriers apply schedule-rating credits of 5–15% for a clean five-year claims record, hospital-affiliation credits of 5–10% where the surgeon carries group or institutional endorsements, and debits of 10–30% or more for paid claims, open reserves, or disciplinary proceedings. The same zip code, the same specialty code, and the same limits can therefore produce quotes that differ by 40% or more based solely on individual underwriting. For a concrete example of how a seven-figure verdict flows through a NY physician's coverage stack, see our analysis of the real cost of a $2M malpractice verdict to a NY physician.

Hospital-employed versus private practice coverage

A hospital-employed NY general surgeon is usually covered under the employer's self-insured trust or captive insurance company, typically at $2M/$6M limits, while a private-practice surgeon purchases an individual-named policy from MLMIC, EmPRO, or TDC. The coverage gap that matters is the overlap between the two models: moonlighting, locum work, asset-protection excess, and the claims-history portability that determines future premium when the surgeon transitions between settings.

When the employer's policy is enough

For a full-time academic or health-system-employed general surgeon whose clinical scope is confined to the employer's facilities, the employer's trust or captive usually provides adequate primary coverage. NY teaching hospitals typically carry $2M/$6M primary layers through a captive, often supplemented by an excess layer of $5M–$25M for nuclear-verdict protection. The surgeon is a named insured under the captive's bordereau, and defense counsel is selected from a pre-approved panel managed by the captive's claims team.

Two details separate an adequate employer policy from an inadequate one. First, the consent-to-settle clause: a well-drafted policy either requires the surgeon's consent before settling a claim over a defined threshold, or provides hammer-clause protection that caps the surgeon's exposure if consent is withheld. Second, the reporting endorsement: the policy must extend to claims reported after employment ends for care rendered during employment. Without that extension, the surgeon carries uninsured tail on exit.

When individual-named coverage is needed

Three situations push a hospital-employed surgeon into needing individual-named coverage. First, moonlighting or locum work outside the employer's facilities, which the employer's policy often explicitly excludes. A NY general surgeon covering weekend call at a second hospital or consulting at an ASC should carry an individual policy with the second-location endorsement scheduled on the declarations page.

Second, personal asset protection when a nuclear verdict exceeds the employer's primary and excess limits. NY's no-damage-caps regime means a $25M verdict is not hypothetical, and the portion above the combined employer and excess limits attaches to the surgeon personally unless an individual umbrella or personal excess malpractice policy sits above. For surgeons with substantial personal assets, brokers typically recommend $1M–$5M of personal excess malpractice layered above the employer's stack.

Third, portability of claims history when the surgeon transitions to private practice. A surgeon covered exclusively under a hospital trust for a decade accumulates no individual carrier claims record, and the first voluntary-market quote on exit may price the surgeon as if she were a first-year graduate. Carrying a $100K–$250K individual-named "doctor-in-charge" policy in parallel with the employer's trust, even during employed years, preserves the claims-history file that future carriers use to set rate.

NYC teaching hospital specifics

Several of the NYC academic medical centers require general surgeons to carry personal excess limits above the captive's primary. Limits requirements vary institution to institution; $1M/$3M personal excess is a common minimum, and $5M excess appears at a handful of institutions for surgeons in the highest-severity sub-specialties. The surgeon's credentialing packet will list the current requirement, and the employing department's chair typically negotiates whether the institution or the surgeon pays the premium.

Vicarious-liability endorsements round out the structure. When a general surgeon supervises residents, fellows, physician assistants, or registered nurses, the supervising surgeon can be named on a claim arising from the supervised provider's action even when the surgeon was not physically present. Well-drafted policies include a vicarious-liability endorsement at no additional charge; lower-tier carriers sometimes require a separate endorsement at a 5–10% premium add. For a surgeon supervising a large residency or APP team, confirming the vicarious-liability language is worth a 15-minute policy review. Our physicians industry page covers the employer-versus-individual structure in broader context, and the professional liability service page details what a Morningside broker review of an employer policy typically surfaces.

Lavern's Law impact on tail decisions

Lavern's Law, the 2018 amendment to NY CPLR 214-a, resets the 2½-year statute of limitations on cancer and malignant-tumor misdiagnosis claims to run from the date of discovery, capped at 7 years from the alleged negligence. For a general surgeon who resects specimens that are later diagnosed as cancer, missed at final pathology review, or down-staged inaccurately, the Lavern's Law window extends the reporting tail well past the historic 5-year employment-contract default. A 7-year extended reporting endorsement, not a 5-year default, now matches the legal reality.

What Lavern's Law changed for claims-made policies

Before Lavern's Law, a NY general surgeon terminating a claims-made policy could reasonably buy a 5-year tail and assume coverage aligned with the 2½-year statutory window plus the typical continuous-treatment tolling. The amendment changed that math for cancer-adjacent cases. A patient who undergoes colon resection in 2024, returns to primary care through 2027, and is diagnosed with metastatic recurrence in 2029 can now bring a claim in 2030 against the 2024 resection, within the 6-year discovery window capped at 7 years from the negligence.

For the surgeon who retired in 2027, that 2030 claim report falls within the Lavern's Law window but outside a 5-year tail purchased at retirement. The practical fix is to extend the extended reporting endorsement to match the 7-year statutory cap on cancer discovery claims. Carriers typically accommodate this at a marginal cost above the standard 5-year tail: the incremental 2 years of reporting coverage adds roughly 10–15% to the tail multiplier, not a full proportional increase, because the reserve-development curve flattens in the later years.

Which general surgery specimens carry Lavern's Law exposure

Not every general surgery case implicates Lavern's Law. The amendment applies specifically to cancer and malignant-tumor misdiagnosis claims, so the operative-pathology link is the determining factor. Colon resections for polyps with high-grade dysplasia or margin-positive adenocarcinoma, breast lumpectomies with missed margins, pancreatic resections where the frozen section and final pathology diverge, and lymph node dissections where a secondary primary is identified months later are the common pathways.

General surgeons with a significant oncologic case mix, hepatobiliary, colorectal, breast surgical oncology, should carry the 7-year reporting window as a baseline. Surgeons whose practice is concentrated in hernia, gallbladder, and appendix cases carry lower cancer-adjacent exposure, though a cholecystectomy that misses an incidentally seen malignant finding on imaging still falls within Lavern's Law's reach. CPLR 214-a's full text defines the precise triggering conditions, and a broker review of past five years of operative cases against the statute's criteria is typically the fastest way to size the tail requirement.

Reporting implications at retirement or job change

The reporting implications translate directly to tail-purchase decisions at retirement, job change, or specialty shift. A NY general surgeon retiring in 2026 is still exposed to Lavern's Law reports through 2033 for cancer-adjacent cases performed in 2026. A 5-year tail expires in 2031, two years short. The options are a 7-year extended reporting endorsement, an occurrence-policy conversion on the final year of practice, or a free-tail provision in the employment contract that waives the buyout at retirement, disability, or death.

Free-tail provisions are becoming more common in NY general surgery employment contracts. A typical trigger language waives tail cost if termination follows retirement at age 55 or older with at least 5 years of continuous coverage, total permanent disability, or death. Surgeons negotiating a new contract should push for a free-tail trigger on retirement and disability at minimum, and should specifically reference a 7-year reporting window, not a 5-year default, to capture the Lavern's Law statutory cap.

How Lavern's Law changes the tail cost-benefit

The cost-benefit math on tail has shifted with Lavern's Law. A Manhattan general surgeon at the top of the statewide base range faces a tail buyout in the $200K–$250K range at a 5-year reporting window and roughly $225K–$285K at a 7-year window. The incremental $25K–$40K for the extra 2 years is small relative to the defense and indemnity exposure of an uncovered Lavern's Law claim, which can easily run into seven figures.

The practical drafting fix is simple. A physician's tail endorsement should reference a 7-year reporting period for cancer-adjacent care and should incorporate CPLR 214-a discovery-rule language so future amendments to the statute track automatically. For related NY specialty context on how statute shifts flow through to premium decisions, see our OB/GYN pillar guide and orthopedic surgery pillar guide, both of which treat the same statutory backdrop from different specialty angles.

Talk to a broker before the next renewal

NY general surgery malpractice pricing rewards precision. The right carrier, the right retro date, the right tail structure, and the right scope-of-practice endorsements can move a surgeon's career cost of coverage by six figures. A 30-minute conversation with a broker appointed across MLMIC, EmPRO, The Doctors Company, MedPro, and Coverys is usually the highest-value hour in a renewal cycle or a contract negotiation, especially when a carrier switch or a transition between hospital employment and private practice is on the table. You can request a quote or schedule a consultation when you are ready.